7Niu C,Yan H,Yu T,et al.Studies on treatment of acute promyelocytic leukemia with arsenic trioxide:remission indection,follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.Blood,1999,94:3315-24.
8Roberts TE,Sprague K,Schenkein D,et al.Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction[J].Blood,2000,96:4000-1.
9Camosino I,Lataglatia R,Avvisati G,et al.Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia[J].Haematologica,2004,89:615-7.
10Wing-Yan Au,Cyrus R,Kumana,et al.Oral arsenic trioxide in the treatment of relapsed acute promyelocyte leukemia[J].Blood,2003,102(1):407-8.
7Larrea MD, Wander SA, Slingerland JM. P27 as Jekyll and Hyde: Regulation of cell cycle and cell motility [ J]. Cell Cycle, 2009, 8 (21) : 3455-3461.
8Lee J, Kim SS,The function of P27 KIP1 during tumor development [J]. Exp Mol Med, 2009, 41(11): 765-771.
9Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of P27Kipl , a cyelin-dependent kinase inhibitor and a potential mediator of extraeellular antimitogentic signals [J]. Cell, 1994, 78( 1 ): 59-66.
10Ray A, James MK, Larochelee S, Fisher RP, Blain SW. P27Kipl inhibits eyelin D-eyclin-dependent kinase 4 by two independent modes [J]. Mol Cell Biol, 2009, 29(4) : 986-999.
